Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.58 USD
+0.18 (2.81%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $6.57 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVCT 6.58 +0.18(2.81%)
Will NVCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCT
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
NVCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 10th
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree
Other News for NVCT
7 Penny Biotech Stocks to Triple Your Investment
Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Strong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug Trials
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024